Resumen de Biomedikuntzan aplikazio teranostikoak izan ditzaketen rHDL-AuNC konplexu hibridoen garapena

Endika Cabrera Antón, V. Rubio López, Teresa Herranz, Beñat Larrañaga Monasterio, Telmo Santamaría Zamorano, Aitor Ordeñana Manso, Shifa Jebari Benslaiman, Unai Galicia Garcia, Asier Larrea Sebal, César Augusto Martín Plágaro, Asier Benito Vicente

• English

  Although advances have been made in the diagnosis of diseases and the development of therapies, it is essential to develop more specific approaches so that the transition to personalized medicine can take place. One of the approaches that may be useful for this is nanobiotechnology. This discipline promotes the development of innovative materials, devices, or techniques by taking advantage of the nanoscale manipulation of biological systems and their components. In this regard, hybrid structures composed of apolipoprotein A-1 (ApoA-1) protein and gold nanoclusters (clusters of < 100 gold atoms) can provide an innovative perspective. Gold nanoclusters (AuNCs) have interesting properties other than larger nanoparticles, such as fluorescent properties, that can be useful for diagnosis or the following-up of treatments. On the other hand, ApoA-1 is one of the major components of high clinical interest HDL particles IkerGazte 2025 Zientziak eta Natura Zientziak323 ("good" cholesterol) and plays a central role in the process of recapturing excess cholesterol, presenting a therapeutic effect on cardiovascular diseases. Thus, these generated proteo -metallic hybrids can become complexes of great clinical interest, as they can be used as nanotools for both diagnosis and therapy, meaning they provide the ability to develop theragnostic tools . For this purpose, recombinant human-origin ApoA-1 was produced, and ApoA-1-AuNC proteo-metallic hybrids were created using established synthetic methods. Once these compounds were built, they were characterized, and it was confirmed that they could form recombinant HDL-like nanoplatforms (rHDL-AuNC). In summary, this work has succeeded in creating a new combination between ApoA-1 and AuNCs as a biotechnological advancement. Looking to the future, it will be important to study the biocompatibility of these new hybrids as well as to demonstrate their usefulness in theranostic applications.

• euskara

  Gaixotasunen diagnostikoan eta terapien garapenean aurrepenak eman diren arren, funtsezkoa da ikuspuntu espezifikoagoak garatzea medikuntza pertsonalizatu baterako trantsizioa eman dadin. Horretarako baliagarria suerta daitekeen ikuspuntuetako bat nanobioteknologia da. Disziplina honek sistema biologikoen zein horien osagaien nanoeskala mailako manipulazioaz baliatuta material, dispositibo edota teknika berritzaileen garapena sustatzen du. Horren harira, apolipoproteina A-1 (ApoA-1) proteinaz eta urrezko nanokluster rez (100 atomo edo gutxiagoko urrezko multzokaketak) osatutako egitura hibridoek ikuspuntu berritzaile bat eman dezakete. Nanok luster rek (AuNC) urrezko nanopartikula handiagoek ez bezalako propietate interesgarriak dituzte, hala nola fluoreszentzia, diagnostikorako edota tratamentuen jarraipenerako baliagarriaizan daitekeena. Bestetik, ApoA-1 interes kliniko handia duten HDL partikulen (kolesterol “onaren”) osagaietako bat da eta soberazko kolesterolaren birkaptazio prozesuan funtzio nagusia du, gaixotasun kardiobaskularretan efektu terapeutikoa aurkeztuz. Hortaz, sortutako hibrido proteo-metaliko horiek interes kliniko handiko konplexuak suerta daitezke diagnostikorako zein terapiarako nanotresna gisa erabili daitezkeelako, hau da, herramienta teranostikoak gauzatzeko ahalmena ematen dutelako. Testuinguru horretan, ApoA-1 eta AuNC barnebiltzen dituzten egiturak sintetizatu dira ikerketa lan honetan. Horretarako giza jatorrizko ApoA-1 errekonbinanteki ekoitzi zen eta ezarritako metodo sintetikoen bidez ApoA-1- AuNC hibridoproteo-metalikoak sortu ziren. Behin konposatu horiek eraikita, karakterizatu eta HDL antzekonanoplataforma birkonbinatuak (rHDL-AuNC) sortzeko gai zirela baieztatu zen. Guztira, lan honetan aurrerapen bioteknologiko gisa ApoA-1 eta AuNCn arteko konbinaketa berria sortzea lortu da. Etorkizunera begira, hibrido berrien biobateragarritasuna aztertzea garrantzizkoa izango da, hala nola helburu teranostikoa duten aplikazioetan erabilgarriak diren frogatzea